Glonova

Glonova is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the discovery and development of next-generation oncology therapeutics. The company focuses on targeting well-validated but difficult-to-drug pathways, with a particular emphasis on KRAS-driven malignancies. Their lead program, GLN-1001, is a selective small molecule KRAS G12C inhibitor currently undergoing clinical evaluation in patients with advanced solid tumors. Glonova is backed by prominent venture capital firms, including Decheng Capital, and is led by a management team with extensive experience in global pharmaceutical R&D. The company aims to provide innovative treatment options for cancer patients with high unmet medical needs through a precision medicine approach. In addition to its lead candidate, the company is advancing a discovery-stage pipeline of targeted therapies designed to overcome resistance mechanisms in cancer.